This page shows the latest ribociclib news and features for those working in and with pharma, biotech and healthcare.
In addition, sales of the company’s plaque psoriasis treatment Cosentyx (secukinumab) increased by 7%, with its HER2-negative breast cancer therapy Kisqali (ribociclib) also growing by 50%.
According to NICE, Ibrance now joins two other of its approved drugs – Novartis’ Kisqali (ribociclib) and Lilly’s Verzenio (abemaciclib) - as a treatment option for patients at this stage of the
It also has plans to expand wet AMD therapy Beovu(brolucizumab-dbll) and HER-2 breast cancer treatments Piqray (alpelisib) and Kisqali(ribociclib) into additional indications to help drive growth.
However, shortly after the top-line data were announced, Novartis reported results with a trial of its rival CDK4/6 inhibitor Kisqali (ribociclib) which stole some of Lilly’s thunder.
from new prostate cancer therapy Lutathera, Kisqali (ribociclib) for breast cancer and CAR-T Kymriah (tisagenlecleucel).
The CDK 4/6 inhibitor looks set to remain one of Pfizer’s biggest growth brands – despite competition from rival products such as Lilly’s Verzenio (abemaciclib) and Kisqali (ribociclib) from
More from news
Approximately 4 fully matching, plus 33 partially matching documents found.
East. Most recently, Semerjian served as senior vice president and global launch head of ribociclib.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...